
    
      This study was designed to provide one year efficacy and safety data for subcutaneous (SC)
      omalizumab, compared to placebo in children (6 to < 12 years) with moderate to severe
      persistent asthma who have inadequate asthma control despite treatment according to National
      Heart, Lung and Blood Institute (NHLBI) step 3 or 4 (at least medium dose inhaled
      corticosteroids with or without other controller asthma medications).
    
  